Norplant: Reversible Implant Contraception

Through two years of comparative clinical trials, Norplant, a subdermal contraceptive implant system containing the synthetic progestin levonorgestrel, has had a net cumulative pregnancy rate of 0.4 per hundred. This rate was significantly below rates for another implant contraceptive and for the TC...

Full description

Saved in:
Bibliographic Details
Published in:Studies in family planning 1980-07, Vol.11 (7/8), p.227-235
Main Authors: Sivin, Irving, Robertson, Dale N., Stern, Janet, Croxatto, Horacio B., Diaz, Soledad, Coutinho, Elsimar, da Silva, Ana Rita, Sanchez, Francisco Alvarez, Faundes, Anibal, McDonald, Olivia, Holma, Pentii, Nielson, Niels C., Osler, Mogens, Nash, Harold A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Birth control
Bleeding
Capsules
Clinical Trials as Topic
Contraception
Contraceptive Agents
Contraceptive implants
Dosage
Double-Blind Method
Drug Implants
Family planning
Female
Humans
Intrauterine devices
Intrauterine Devices, Copper - adverse effects
Menstruation Disturbances - etiology
Norgestrel - adverse effects
Norgestrel - pharmacology
Norgestrienone - adverse effects
Norgestrienone - pharmacology
Pregnancy
Pregnancy rate
Scandinavian and Nordic Countries
South America
West Indies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Through two years of comparative clinical trials, Norplant, a subdermal contraceptive implant system containing the synthetic progestin levonorgestrel, has had a net cumulative pregnancy rate of 0.4 per hundred. This rate was significantly below rates for another implant contraceptive and for the TCu 200. The major side effect of the method has been irregular bleeding. The experience of the pilot clinical study through three years and the release rates of levonorgestrel from the implanted capsules indicated that a single administration of Norplant will provide effective protection against pregnancy for at least five years.
ISSN:0039-3665
1728-4465
DOI:10.2307/1966240